Colorectal Cancer

The combination of onvansertib plus FOLFIRI/bevacizumab showed promise among patients with KRAS-mutated metastatic colorectal cancer.

Higher corticosteroid peak dose may worse progression-free and overall survival in several tumor types including melanoma, non-small cell lung cancer, and others.

Olanzapine improved control of nausea and vomiting from moderately emetogenic chemotherapy, which may suggest its use as a standard of care for antiemetic prophylaxis.

The FDA approved the Shield blood test for colorectal screening in adults aged 45 years and older with an average risk for the disease.

Nivolumab plus ipilimumab improved health-related quality of life and reduced symptom burden in patients with microsatellite instability–high/mismatch repair–deficient mCRC.

Disease-free survival and overall survival improved with celecoxib plus advanced chemotherapy in patients with PIK3CA-mutated stage III colon cancer.

Throughout June, the FDA approved drugs for the treatment of diseases including myelodysplastic syndrome, thyroid cancer, endometrial cancer, colorectal cancer, and follicular lymphoma.

Nurses can educate patients on dietary habits that may increase colorectal cancer risk.

Accelerated approval has been granted to adagrasib for use with cetuximab in previously treated adults with KRAS G12C-mutated locally advanced or metastatic colorectal cancer.

Using an artificial intelligence-based navigation tool to contact patients who missed their colonoscopy appointment may help them reschedule and potentially attend a new appointment.

A screening test has been approved by the FDA for adults 45 years of age or older with an average risk for developing colorectal cancer.

Patients with metastatic microsatellite stable colorectal cancer treated with a personalized neoantigen cancer vaccine after chemotherapy demonstrated an early trend towards a progression-free survival benefit.

A next-generation stool DNA test had higher sensitivity for CRC and advanced precancerous lesions but lower specificity for advanced neoplasia compared with a fecal immunochemical test.

Oncology nurses can inform patients about the probability of identifying advanced neoplasia using stool-based screening tools.

Priority review was granted by the FDA to a supplemental new drug application for adagrasib plus cetuximab for the treatment of advanced KRAS G12C–mutated colorectal cancer.

Favorable ECOG performance status and less advanced disease may predict which patients with metastatic colorectal cancer might have long-term remission when treated with regorafenib.

Consuming navy beans daily as a dietary intervention may contribute to the health of the body's microbiome.

First-line treatment with nivolumab plus ipilimumab for patients with microsatellite instability–high or mismatch repair deficient metastatic colorectal cancer can be considered a standard-of-care option based on results from the phase 3 CheckMate-8HW trial.

Fruquintinib showed potential in providing an improved quality of life and survival benefit in patients with previously treated metastatic colorectal cancer.

Detecting minimal residual disease with ctDNA in patients with stage II/III colorectal cancer may strongly predict disease recurrence and the potential benefit from adjuvant chemotherapy.

The median overall survival was 77.5 months with frontline pembrolizumab vs 36.7 months with chemotherapy in patients with microsatellite instability–high or mismatch repair–deficient metastatic colorectal cancer.

Holly Chitwood, DNP, APRN, FNP-C, AGACNP-BC, shares her real-world experience with circulating-tumor-DNA monitoring in the colorectal cancer setting.

Tammy Triglianos, DNP, ANP-BC, AOCNP, discusses optimal adjuvant treatment approaches for patients with stage III colon cancer.

The FDA has approved fruquintinib to treat adults with metastatic colorectal cancer.

Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.